丙型肝炎与阿片类使用障碍在注射吸毒者中的同步启动治疗
这项前瞻性开放标签观察性试验在华盛顿特区减害组织的中转中心纳入100例慢性HCV感染、阿片类使用障碍且持续注射吸毒的患者,给予12周索磷布韦-维帕他韦并 offer 丁丙诺啡起始。82例(82%)获得SVR,与基线OAT状态、治疗期间吸毒或每日依从性不完美无关,但与完成≥2瓶28片索磷布韦-维帕他韦及第24周接受OAT显著相关;接受OAT与更少阿片阳性尿检、更低HIV风险行为评分及更低阿片过量率相关。
要点
- 同步启动OAT与HCV治疗可获得高SVR率(82%)并降低吸毒相关风险。
- SVR与完成≥2瓶28片索磷布韦-维帕他韦及第24周接受OAT显著相关。
- 接受OAT与更少阿片阳性尿检、更低HIV风险行为评分和更低阿片过量率相关。
核心结论
- 在注射吸毒者中同步启动OAT与HCV治疗可获得高SVR率并减少吸毒相关风险。
研究设计与样本
- 前瞻性、开放标签、观察性试验,在华盛顿特区减害组织的中转中心纳入100例慢性HCV感染、阿片类使用障碍且持续注射吸毒的患者。
- 患者接受索磷布韦-维帕他韦治疗12周,并被提供丁丙诺啡起始。
主要发现
- 82例(82%)获得SVR。
- SVR与基线OAT状态(P = .33)、治疗期间吸毒(P >.99)或每日依从性不完美(P = .35)无关。
- SVR与完成2瓶或以上28片索磷布韦-维帕他韦(P < .001)及第24周接受OAT(P = .01)显著相关。
- 基线未接受OAT的67例中53例(79%)起始OAT;第24周68例(68%)接受OAT。
- 接受OAT与更少阿片阳性尿检(P = .003)、更低HIV风险行为评分(P < .001)及更低阿片过量率(P = .04)相关。
临床怎么用
- 可在减害机构中为注射吸毒的HCV感染者同步提供丁丙诺啡起始与HCV治疗。
- 应关注完成足够疗程药物(≥2瓶28片索磷布韦-维帕他韦)及第24周维持OAT以支持SVR。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People who inject drugs have a high prevalence of hepatitis C virus (HCV) and significant disease associated with drug use; however, HCV treatment often occurs in absence of interventions to address opioid use disorder and drug use-related harms. The impact of concurrent initiation of opioid agonist therapy (OAT) on HCV treatment and drug use outcomes is unknown. METHODS: In this prospective, open-label, observational trial at a harm reduction organization's drop-in center in Washington, DC, 100 patients with chronic HCV infection, opioid use disorder, and ongoing injection drug use were treated with sofosbuvir-velpatasvir for 12-weeks and offered buprenorphine initiation. The primary end point was sustained virologic response (SVR), and secondary end points included uptake of and retention in OAT, change in risk behavior, and determinants of SVR. RESULTS: Eighty-two patients (82%) achieved SVR, which was not associated with baseline OAT status (P = .33), on-treatment drug use (P >.99), or imperfect daily adherence (P = .35) but was significantly associated with completing 2 or more 28-pill bottles of sofosbuvir-velpatasvir (P < .001) and receiving OAT at week 24 (P = .01). Of 67 patients not already receiving OAT at baseline, 53 (79%) started OAT. At week 24, 68 (68%) patients were receiving OAT. Receipt of OAT was associated with fewer opiate-positive urine drug screens (P = .003), lower human immunodeficiency virus risk-taking behavior scores (P < .001), and lower rates of opioid overdose (P = .04). CONCLUSIONS: The Novel Model of Hepatitis C Treatment as an Anchor to Prevent HIV, Initiate Opioid Agonist Therapy, and Reduce Risky Behavior study demonstrates high uptake of buprenorphine collocated with HCV treatment, and it shows that concurrent initiation of OAT with HCV treatment can result in high rates of SVR while reducing risks associated with drug use. CLINICAL TRIALS REGISTRATION: NCT03221309.
引用
- Rosenthal ES, Silk R, Mathur P, et al. Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs. Clin Infect Dis. 2020. PMID: 32009165. doi:10.1093/cid/ciaa105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。